PlumX Metrics
Embed PlumX Metrics

Glycated albumin in the detection of diabetes during COVID-19 hospitalization

PLoS ONE, ISSN: 1932-6203, Vol: 19, Issue: 3 March, Page: e0297952
2024
  • 1
    Citations
  • 0
    Usage
  • 3
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

Background Diabetes has emerged as an important risk factor for COVID-19 adverse outcomes during hospitalization. We investigated whether the measurement of glycated albumin (GA) may be useful in detecting newly diagnosed diabetes during COVID-19 hospitalization. Methods In this cross-sectional test accuracy study we evaluated HCPA Biobank data and samples from consecutive in-patients, from 30 March 2020 to 20 December 2020. ROC curves were used to analyse the performance of GA to detect newly diagnosed diabetes (patients without a previous diagnosis of diabetes and admission HbA1c ≥6.5%). Results A total of 184 adults (age 58.6 ± 16.6years) were enrolled, including 31 with newly diagnosed diabetes. GA presented AUCs of 0.739 (95% CI 0.642–0.948) to detect newly diagnosed diabetes. The GA cut-offs of 19.0% was adequate to identify newly diagnosed diabetes with high specificity (85.0%) but low sensitivity (48.4%). Conclusions GA showed good performance to identify newly diagnosed diabetes and may be useful for identifying adults with the condition in COVID-19-related hospitalization.

Bibliographic Details

Fernando Chimela Chume; Priscila Aparecida Correa Freitas; Luisa Gazzi Schiavenin; Eduarda Sgarioni; Cristiane Bauermann Leitao; Joíza Lins Camargo; Fabio Vasconcellos Comim

Public Library of Science (PLoS)

Multidisciplinary

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know